Moderna Inc. said it would ask U.S. and European regulators Monday to allow emergency use of its COVID-19 vaccine as new study results confirm the vaccine offers strong protection — ramping up the ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...
Hospitals filled to capacity. Case counts climbing by the hour. Quarantine became routine. It was the beginning of the ...
Cyprus Mail on MSN
Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
Vaccine makers Pfizer PFE.N and BioNTech 22UAy.DE halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to ...
Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...
BioNTech SE reports first-quarter results before the bell Tuesday, with investors focused on whether the German biotech’s oncology pivot can offset a sharp drop in COVID-19 vaccine revenue as losses ...
Pfizer is selling its remaining stake in COVID-19 vaccine partner BioNTech. The U.S. drugmaker is offering about 4.55 million American depositary receipts in an overnight block trade, marketed at ...
(Reuters) -Pfizer Inc said on Thursday it sold a part of its stake in German drugmaker BioNTech SE, more than five years after both firms formed an alliance that yielded a vaccine to combat the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results